SMC green light for rare blood cancer treatment
NHS funding was backed for four medicines
Read More
Tag: Takhzyro
Shire receives EU approval for Takhzyro
Shire has announced that the European Commission has approved its hereditary angioedema (HAE) drug Takhzyro.
Read More
Shire’s HAE drug Takhzyro gets green light in the US
Shire’s Takhzyro has been approved in the US for the prevention of attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
